Sir,
In the March 8 issue, Ohwada et al (2004) reported a randomised study of patients with stage II or III colorectal cancer, treated with either UFT alone or the combination of UFT and PSK. The benefit obtained by PSK seems impressive, with a decrease by 43.6% in the risk of recurrence and 5-year disease-free survival of 73%, especially as there were only 139 patients in the investigational group and 68 in the control group. Nevertheless, several aspects must be discussed. The first point is the choice of the control arm. The combination of 5-FU and leucovorin currently is the standard adjuvant chemotherapy of colorectal cancer in most countries. There is currently no evidence that UFT, even when modulated by leucovorin, is superior to this regimen. On the contrary, a large phase III trial comparing UFT/leucovorin with 5-FU/LV (Mayo Clinic regimen) in 816 patients with metastatic disease resulted in an increase by 22% in the risk of disease progression in the investigational arm (Douillard et al, 2002). Another randomised study showing some benefit in terms of survival for cancer death only used oral 5-FU in the control arm (Ito et al, 2004). Of note is the high proportion of patients with rectal cancer, reaching 50% in the control group. Given the impact of the quality of surgery and radiotherapy in this location, a confusing factor might have been introduced especially as preoperative radiotherapy has not been administered. The study design introduces several variables in chemotherapy such as early start, long duration, sequential administration of MMC and UFT, introducing other confusing factors. The early start of chemotherapy might be interesting since surgery provokes the circulation of neoplastic cells (Yamaguchi et al, 2000) and angiogenesis and potentially the development of micrometastasis. Intravenous chemotherapy usually starts 4–8 weeks after surgery. Nevertheless, the poor results of the control arm do not support this approach. On a psychological viewpoint, the impact of a very long treatment should not be neglected since it may enforce the idea that cancer can relapse any time. The results in stage III patients in the control arm are poor and question about the efficacy of UFT and MMC. Indirectly, the mediocrity of UFT alone minimises the impact of PSK. The authors largely invoke indirect comparisons with studies published more than 10 years before while many procedures, including surgery, improve over time and promising trials of combination chemotherapy with either oxaliplatin or irinotecan are ongoing. The impact of secondary surgery as well as second-line chemotherapy in well-followed patients may be important in terms of overall survival. The issue of the mechanism of action of PSK, in particular its synergy with a fluoropyrimidine, is intriguing. Since decades, a tremendous number of studies regarding immunotherapy have been reported. Although extracts of microbial agents can logically induce demonstrable production of interleukin-2, interferon, or activated immune cells, evidence of a clinical impact remains extremely limited. Even high-dose interleukin-2 or interferon result only in a modest efficacy in subgroups of patients with cancers partially dependant on immunesurveillance such as advanced renal cancer or melanoma. The efficacy of interferon in the adjuvant therapy of melanoma is highly debated (Sabel and Sondak, 2003). Recent randomised studies have shown that neither interferon (Messing et al, 2003) nor interleukin-2 (Clark et al, 2003) improve survival in the adjuvant treatment of high-risk renal carcinoma. Consequently, the impact of ‘soft’ immunotherapy is difficult to advocate in colorectal cancer. In addition, several recent randomised studies have called into question the efficacy of levamisole (QUASAR Collaborative Group, 2000; Dencausse et al, 2002; Cascinu et al, 2003). Probably, an alternative mechanism should be considered. Inhibition of metastases by protection of vascular membrane basement has also been evoked (Kudo et al, 2002). In conclusion, although PSK remains a good candidate for convenient adjuvant therapy, this study is not definitively convincing. The challenge remains crucial since oral therapy is particularly adapted to the vast concerned population, particularly in the elderly, given the relatively heavy procedure of combination chemotherapy with FOLFOX or FOLFIRI regimen.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cascinu S, Catalano V, Piga A, Matioli R, Marcellini M, Pancotti A, Bascioni R, Torresi U, Silva RR, Pieroni V, Giorgi F, Catalano G, Cellerino R (2003) The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone. Cancer Invest 21: 701–707
Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Grodon MS, Margolin KA (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomised trial. J Clin Oncol 21: 3133–3140
Dencausse Y, Hartung G, Sturm J, Kopp-Schneider A, Hagmuller E, Wojatschek C, Lindemann H, Fritze D, Queisser W (2002) Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie 25: 426–430
Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605–3616
Ito K, Nakazato H, Koike A, Takagi H, Saji S, Baba S, Mai M, Sakamoto J, Ohashi Y (2004) Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 19: 157–164
Kudo S, Tanaka J, Kashida H, Tamegai Y, Endo S, Yamano HO (2002) Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker. Oncol Rep 9: 635–638
Messing EM, Manola J, Wilding G, Propert K, Fleischman J, Crawford ED, Pontes JE, Hahn R, Trump D (2003) Phase III study of interferon alfa-NL as adjuvant treatment for respectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–1222
Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y (2004) Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer. Br J Cancer 90: 1003–1010
QUASAR Collaborative Group (2000) Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 355: 1588–1596
Sabel MS, Sondak VK (2003) Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 8: 451–458
Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S (2000) Significant detection of circulating cancer cells in the blood by reverse transcriptase–polymerase chain reaction during colorectal cancer resection. Ann Surg 232: 58–65
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Alliot, C. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer. Br J Cancer 91, 1220–1221 (2004). https://doi.org/10.1038/sj.bjc.6602100
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6602100